Dermapharm Holding SE
DMPHF
$38.50
-$2.12-5.23%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.35% | 5.09% | 3.96% | 1.82% | 2.80% |
| Total Other Revenue | 75.14% | 75.14% | 75.14% | 80.86% | 80.86% |
| Total Revenue | 4.38% | 5.11% | 3.99% | 1.83% | 2.81% |
| Cost of Revenue | 0.79% | 1.52% | -0.19% | 1.12% | 3.46% |
| Gross Profit | 6.57% | 7.39% | 6.64% | 2.26% | 2.42% |
| SG&A Expenses | 5.20% | 5.85% | 6.02% | 14.98% | 27.01% |
| Depreciation & Amortization | -4.29% | -12.84% | -7.53% | 32.07% | 6.25% |
| Other Operating Expenses | 1.84% | 4.33% | 5.00% | -6.64% | -0.58% |
| Total Operating Expenses | 1.82% | 1.79% | 1.70% | 5.60% | 9.01% |
| Operating Income | 16.69% | 23.07% | 15.33% | -12.18% | -19.28% |
| Income Before Tax | 26.14% | 55.86% | 63.26% | -7.94% | -30.55% |
| Income Tax Expenses | 17.92% | 21.35% | 32.95% | -17.52% | -32.24% |
| Earnings from Continuing Operations | 31.10% | 84.64% | 86.10% | -1.22% | -29.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -42.73% | -19.14% | 10.36% | -34.32% | 19.04% |
| Net Income | 29.15% | 80.85% | 83.86% | -1.90% | -28.72% |
| EBIT | 16.69% | 23.07% | 15.33% | -12.18% | -19.28% |
| EBITDA | 12.02% | 11.37% | 8.59% | -10.80% | -20.18% |
| EPS Basic | 29.48% | 80.95% | 83.57% | -2.02% | -29.22% |
| Normalized Basic EPS | 22.20% | 48.23% | 55.95% | -21.67% | -30.79% |
| EPS Diluted | 29.48% | 80.95% | 83.57% | -2.02% | -29.22% |
| Normalized Diluted EPS | 22.20% | 48.23% | 55.95% | -21.67% | -30.79% |
| Average Basic Shares Outstanding | -0.41% | -0.26% | -0.21% | 0.02% | 0.43% |
| Average Diluted Shares Outstanding | -0.41% | -0.26% | -0.21% | 0.02% | 0.43% |
| Dividend Per Share | 1.27% | 1.27% | 1.27% | -11.69% | -11.69% |
| Payout Ratio | -- | -0.53% | -0.54% | -0.14% | -1.00% |